This led us to explore whether other SGLT2i, particularly canagliflozin, which has received less attention, could exert their protective effects on diabetic cardiomyopathy through enhancing mitophagy, especially the PINK1-Parkin-dependent pathway. This evidence concerns the gene PRKN and diabetic cardiomyopathy.